TY - JOUR
T1 - Critical roles for PU.1, GATA1, and GATA2 in the expression of human FcεRI on mast cells
T2 - PU.1 and GATA1 transactivate FCER1A, and GATA2 transactivates FCER1A and MS4A2
AU - Inage, Eisuke
AU - Kasakura, Kazumi
AU - Yashiro, Takuya
AU - Suzuki, Ryuyo
AU - Baba, Yosuke
AU - Nakano, Nobuhiro
AU - Hara, Mutsuko
AU - Tanabe, Atsushi
AU - Oboki, Keisuke
AU - Matsumoto, Kenji
AU - Saito, Hirohisa
AU - Niyonsaba, François
AU - Ohtsuka, Yoshikazu
AU - Ogawa, Hideoki
AU - Okumura, Ko
AU - Shimizu, Toshiaki
AU - Nishiyama, Chiharu
PY - 2014/4/15
Y1 - 2014/4/15
N2 - The high-affinity IgE receptor, FcεRI, which is composed of α-, β-, and γ-chains, plays an important role in IgE-mediated allergic responses. In the current study, involvement of the transcription factors, PU.1, GATA1, and GATA2, in the expression of FcεRI on human mast cells was investigated. Transfection of small interfering RNAs (siRNAs) against PU.1, GATA1, and GATA2 into the human mast cell line, LAD2, caused significant downregulation of cell surface expression of FcεRI. Quantification of the mRNA levels revealed that PU.1, GATA1, and GATA2 siRNAs suppressed the α transcript, whereas the amount of β mRNA was reduced in only GATA2 siRNA transfectants. In contrast, γ mRNA levels were not affected by any of the knockdowns. Chromatin immunoprecipitation assay showed that significant amounts of PU.1, GATA1, and GATA2 bind to the promoter region of FCER1A (encoding FcεRIα) and that GATA2 binds to the promoter of MS4A2 (encoding FcεRIβ). Luciferase assay and EMSA showed that GATA2 transactivates the MS4A2 promoter via direct binding. These knockdowns of transcription factors also suppressed the IgE-mediated degranulation activity of LAD2. Similarly, all three knockdowns suppressed FcεRI expression in primary mast cells, especially PU.1 siRNA and GATA2 siRNA, which target FcεRIα and FcεRIβ, respectively. From these results, we conclude that PU.1 and GATA1 are involved in FcεRIα transcription through recruitment to its promoter, whereas GATA2 positively regulates FcεRIβ transcription. Suppression of these transcription factors leads to downregulation of FcεRI expression and IgEmediated degranulation activity. Our findings will contribute to the development of new therapeutic approaches for FcεRImediated allergic diseases.
AB - The high-affinity IgE receptor, FcεRI, which is composed of α-, β-, and γ-chains, plays an important role in IgE-mediated allergic responses. In the current study, involvement of the transcription factors, PU.1, GATA1, and GATA2, in the expression of FcεRI on human mast cells was investigated. Transfection of small interfering RNAs (siRNAs) against PU.1, GATA1, and GATA2 into the human mast cell line, LAD2, caused significant downregulation of cell surface expression of FcεRI. Quantification of the mRNA levels revealed that PU.1, GATA1, and GATA2 siRNAs suppressed the α transcript, whereas the amount of β mRNA was reduced in only GATA2 siRNA transfectants. In contrast, γ mRNA levels were not affected by any of the knockdowns. Chromatin immunoprecipitation assay showed that significant amounts of PU.1, GATA1, and GATA2 bind to the promoter region of FCER1A (encoding FcεRIα) and that GATA2 binds to the promoter of MS4A2 (encoding FcεRIβ). Luciferase assay and EMSA showed that GATA2 transactivates the MS4A2 promoter via direct binding. These knockdowns of transcription factors also suppressed the IgE-mediated degranulation activity of LAD2. Similarly, all three knockdowns suppressed FcεRI expression in primary mast cells, especially PU.1 siRNA and GATA2 siRNA, which target FcεRIα and FcεRIβ, respectively. From these results, we conclude that PU.1 and GATA1 are involved in FcεRIα transcription through recruitment to its promoter, whereas GATA2 positively regulates FcεRIβ transcription. Suppression of these transcription factors leads to downregulation of FcεRI expression and IgEmediated degranulation activity. Our findings will contribute to the development of new therapeutic approaches for FcεRImediated allergic diseases.
UR - http://www.scopus.com/inward/record.url?scp=84898638725&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1302366
DO - 10.4049/jimmunol.1302366
M3 - Article
C2 - 24639354
AN - SCOPUS:84898638725
SN - 0022-1767
VL - 192
SP - 3936
EP - 3946
JO - Journal of Immunology
JF - Journal of Immunology
IS - 8
ER -